Koedijk JB, van Rijswijk J, Oranje WA, van den Bergh JP, Bours SP, Savelberg HH, et al. Sedentary behaviour and bone health in children, adolescents and young adults: a systematic review. Osteoporos Int. 2017;28:2507–19.
Daniell JR, Osti OL. Failed back surgery syndrome: a review article. Asian Spine J. 2018;12:372–9.
Liu J, Ni B, Zhu L, Yang J, Cao X, Zhou W. Mitomycin C-polyethylene glycol controlled-release film inhibits collagen secretion and induces apoptosis of fibroblasts in the early wound of a postlaminectomy rat model. Spine J. 2010;10:441–7.
Song Z, Wu T, Sun J, Wang H, Hua F, Nicolas YSM, et al. Metformin attenuates post-epidural fibrosis by inhibiting the TGF-β1/Smad3 and HMGB1/TLR4 signaling pathways. J Cell Mol Med. 2021;25:3272–83.
Geudeke MW, Krediet AC, Bilecen S, Huygen FJPM, Rijsdijk M. Effectiveness of epiduroscopy for patients with failed back surgery syndrome: a systematic review and meta-analysis. Pain Pract. 2021;21:468–81.
Li X, Chen S, Yan L, Wang J, Pei M. Prospective application of stem cells to prevent post-operative skeletal fibrosis. J Orthop Res. 2019;37:1236–45.
Wang H, Sun W, Fu D, Shen Y, Chen YY, Wang L. Update on biomaterials for prevention of epidural adhesion after lumbar laminectomy. J Orthop Translat. 2018;13:41–9.
Hallab NJ, Bao QB, Brown T. Assessment of epidural versus intradiscal biocompatibility of PEEK implant debris: an in vivo rabbit model. Eur Spine J. 2013;22:2740–51.
Lefrançais E, Roga S, Gautier V, Gonzalez-de-Peredo A, Monsarrat B, Girard JP, et al. IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proc Natl Acad Sci USA. 2012;109:1673–8.
De la Fuente M, MacDonald TT, Hermoso MA. The IL-33/ST2 axis: role in health and disease. Cytokine Growth Factor Rev. 2015;26:615–23.
Kotsiou OS, Gourgoulianis KI, Zarogiannis SG. IL-33/ST2 axis in organ fibrosis. Front Immunol. 2018;9:2432.
Borthwick LA. The IL-1 cytokine family and its role in inflammation and fibrosis in the lung. Semin Immunopathol. 2016;38:517–34.
Sun Z, Chang B, Gao M, Zhang J, Zou Z. IL-33-ST2 axis in liver disease: progression and challenge. Mediators Inflamm. 2017;2017:5314213.
Yang F, Zhu P, Duan L, Yang L, Wang J. IL33 and kidney disease (Review). Mol Med Rep. 2016;13:3–8.
Dudek M, Kałużna-Oleksy M, Migaj J, Straburzyńska-Migaj E. Clinical value of soluble ST2 in cardiology. Adv Clin Exp Med. 2020;29:1205–10.
Homsak E, Gruson D. Soluble ST2: a complex and diverse role in several diseases. Clin Chim Acta. 2020;507:75–87.
D’Urso M, Kurniawan NA. Mechanical and physical regulation of fibroblast-myofibroblast transition: from cellular mechanoresponse to tissue pathology. Front Bioeng Biotechnol. 2020;8:609653.
Coelho LL, Pereira IR, Pereira MCS, Mesquita L, Lannes-Vieira J, Adesse D, et al. Trypanosoma cruzi activates mouse cardiac fibroblasts in vitro leading to fibroblast-myofibroblast transition and increase in expression of extracellular matrix proteins. Parasit Vectors. 2018;11:72.
Sun Z, Ji N, Ma Q, Zhu R, Chen Z, Wang Z, et al. Epithelial-mesenchymal transition in asthma airway remodeling is regulated by the IL-33/CD146 axis. Front Immunol. 2020;11:1598.
Jin R, Xu J, Gao Q, Mao X, Yin J, Lu K, et al. IL-33-induced neutrophil extracellular traps degrade fibronectin in a murine model of bronchopulmonary dysplasia. Cell Death Discov. 2020;6:33.
Liu J, Peng L, Liu Y, Wu K, Wang S, Wang X, et al. Topical TWEAK accelerates healing of experimental burn wounds in mice. Front Pharmacol. 2018;9:660.
Seluanov A, Vaidya A, Gorbunova V. Establishing primary adult fibroblast cultures from rodents. J Vis Exp. 2010. https://doi.org/10.3791/2033.
Lin M, Guo R, Su Z, Ke S, Zeng D. Combination leflunomide and methotrexate impedes the recovery of liver fibrosis, partly through inhibition of myeloid cell admittance. Mol Med Rep. 2019;19:1622–8.
Bollong MJ, Yang B, Vergani N, Beyer BA, Chin EN, Zambaldo C, et al. Small molecule-mediated inhibition of myofibroblast transdifferentiation for the treatment of fibrosis. Proc Natl Acad Sci U S A. 2017;114:4679–84.
Lipsky BP, Toy DY, Swart DA, Smithgall MD, Smith D. Deletion of the ST2 proximal promoter disrupts fibroblast-specific expression but does not reduce the amount of soluble ST2 in circulation. Eur J Immunol. 2012;42:1863–9.
Molkentin JD, Bugg D, Ghearing N, Dorn LE, Kim P, Sargent MA, et al. Fibroblast-specific genetic manipulation of p38 mitogen-activated protein kinase in vivo reveals its central regulatory role in fibrosis. Circulation. 2017;136:549–61.
Khalil H, Kanisicak O, Prasad V, Correll RN, Fu X, Schips T, et al. Fibroblast-specific TGF-beta-Smad2/3 signaling underlies cardiac fibrosis. J Clin Invest. 2017;127:3770–83.
Luzina IG, Pickering EM, Kopach P, Kang PH, Lockatell V, Todd NW, et al. Full-length IL-33 promotes inflammation but not Th2 response in vivo in an ST2-independent fashion. J Immunol. 2012;189:403–10.
Guo Z, Wu J, Zhao J, Liu F, Chen Y, Bi L, et al. IL-33 promotes airway remodeling and is a marker of asthma disease severity. J Asthma. 2014;51:863–9.
Yanaba K, Yoshizaki A, Asano Y, Kadono T, Sato S. Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. Clin Rheumatol. 2011;30:825–30.
Marvie P, Lisbonne M, L'helgoualc'h A, Rauch M, Turlin B, Preisser L, et al. Interleukin-33 overexpression is associated with liver fibrosis in mice and humans. J Cell Mol Med. 2010;14:1726–39.
Liang H, Xu F, Wen XJ, Liu HZ, Wang HB, Zhong JY, et al. Interleukin-33 signaling contributes to renal fibrosis following ischemia reperfusion. Eur J Pharmacol. 2017;812:18–27.
Vianello E, Dozio E, Tacchini L, Frati L, Corsi Romanelli MM. ST2/IL-33 signaling in cardiac fibrosis. Int J Biochem Cell Biol. 2019;116:105619.
Cayrol C, Girard JP. Interleukin-33 (IL-33): a nuclear cytokine from the IL-1 family. Immunol Rev. 2018;281:154–68.
Luzina IG, Fishelevich R, Hampton BS, Courneya JP, Parisella FR, Lugkey KN, et al. Full-length IL-33 regulates Smad3 phosphorylation and gene transcription in a distinctive AP2-dependent manner. Cell Immunol. 2020;357:104203.
Jin Z, Sun J, Song Z, Chen K, Nicolas YSM, Kc R, et al. Neutrophil extracellular traps promote scar formation in post-epidural fibrosis. NPJ Regen Med. 2020;5:19
Fu J, Lin SH, Wang CJ, Li SY, Feng XY, Liu Q, et al. HMGB1 regulates IL-33 expression in acute respiratory distress syndrome. Int Immunopharmacol. 2016;38:267–74.
Martin NT, Martin MU. Interleukin 33 is a guardian of barriers and a local alarmin. Nat Immunol. 2016;17:122–31.
Shani O, Vorobyov T, Monteran L, Lavie D, Cohen N, Raz Y, et al. Fibroblast-derived IL33 facilitates breast cancer metastasis by modifying the immune microenvironment and driving type 2 immunity. Cancer Res. 2020;80:5317–29.
Cho N, Razipour SE, McCain ML. Featured Article: TGF-β1 dominates extracellular matrix rigidity for inducing differentiation of human cardiac fibroblasts to myofibroblasts. Exp Biol Med (Maywood). 2018;243:601–12.
Tan Z, Liu Q, Jiang R, Lv L, Shoto SS, Maillet I, et al. Interleukin-33 drives hepatic fibrosis through activation of hepatic stellate cells. Cell Mol Immunol. 2018;15:388–98.
Oshio T, Komine M, Tsuda H, Tominaga SI, Saito H, Nakae S, et al. Nuclear expression of IL-33 in epidermal keratinocytes promotes wound healing in mice. J Dermatol Sci. 2017;85:106–14.